Literature DB >> 30739829

Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.

Agha Zeeshan Mirza1, Ismail I Althagafi2, Hina Shamshad3.   

Abstract

The peroxisome proliferator-activated receptors (PPAR-α, PPAR-β/δ, and PPAR-γ) are members of the nuclear receptor super-family, acting as ligand-inducible transcription factors and play crucial roles in glucose and lipid metabolism. These are a well-known receptor for diabetic therapy, not only influence the cardiovascular systems but are also expressed in many human solid tumors. For atherosclerosis, inflammation, and hypertension, the PPARs are considered as important therapeutic targets. Furthermore, it has been suggested that careful designing of partial agonists for PPARs, may show improvement with the side effects and also increase the therapeutic value for different diseases as cancer, inflammation and cardiovascular etc. This review summaries structural features of PPAR receptors, illustrates the method of PPAR modulator design, then analyzes recent dual- and pan-agonist with different therapeutic outcomes of the receptor to be used as a target for drugs in future. The advances in PPARs antagonists, their classification and structure-activity relationship are also summarized.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Peroxisome proliferator-activated receptors; Thiazolidinediones

Mesh:

Substances:

Year:  2019        PMID: 30739829     DOI: 10.1016/j.ejmech.2019.01.067

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  75 in total

Review 1.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

Review 2.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

3.  Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Levels in Adolescent with Bipolar Disorder and Their Relationship with Metabolic Parameters.

Authors:  Meryem Kasak; Mehmet Fatih Ceylan; Selma Tural Hesapcioglu; Almila Senat; Özcan Erel
Journal:  J Mol Neurosci       Date:  2022-03-23       Impact factor: 3.444

Review 4.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 5.  Mechanisms of Myocardial Damage Due to Hyperlipidemia: A Review of Recent Studies.

Authors:  Zhiqi Zhang; Hongyi Wu; Tao Wang; Yao Liu; Chun Meng
Journal:  Med Sci Monit       Date:  2022-09-16

6.  Endocannabinoid-Binding Receptors as Drug Targets.

Authors:  María Gómez-Cañas; Carmen Rodríguez-Cueto; Valentina Satta; Inés Hernández-Fisac; Elisa Navarro; Javier Fernández-Ruiz
Journal:  Methods Mol Biol       Date:  2023

7.  Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.

Authors:  Pasquale Linciano; Barbara De Filippis; Alessandra Ammazzalorso; Pasquale Amoia; Felisa Cilurzo; Marialuigia Fantacuzzi; Letizia Giampietro; Cristina Maccallini; Charlotte Petit; Rosa Amoroso
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

8.  [Research progress of adipose-derived stem cells in skin scar prevention and treatment].

Authors:  Tao He; Jiqiao Yang; Pengcheng Liu; Li Xu; Qing Lü; Qiuwen Tan
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-02-15

9.  Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer.

Authors:  Feng Li; Tingting Lu; Dongmei Liu; Chong Zhang; Yonghui Zhang; Fulu Dong
Journal:  Cell Death Dis       Date:  2021-05-22       Impact factor: 8.469

Review 10.  Targeting Energy Expenditure-Drugs for Obesity Treatment.

Authors:  Carlos M Jimenez-Munoz; Marta López; Fernando Albericio; Kamil Makowski
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.